Raymond James Financial Services Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$567K	Sell	23,028 -207	-0.9%	-$5.04K	﹤0.01%	2530
2024 Q2	$537K	Sell	23,235 -925	-4%	-$21.7K	﹤0.01%	2486
2024 Q1	$582K	Sell	24,160 -3,455	-13%	-$81K	﹤0.01%	2402
2023 Q4	$635K	Buy	27,615 +4,138	+18%	+$83.1K	﹤0.01%	2258
2023 Q3	$478K	Sell	23,477 -11,702	-33%	-$263K	﹤0.01%	2358
2023 Q2	$822K	Sell	35,179 -471	-1%	-$11.3K	﹤0.01%	2039
2023 Q1	$830K	Buy	35,650 +1,492	+4%	+$37.3K	﹤0.01%	2025
2022 Q4	$860K	Sell	34,158 -2,508	-7%	-$67.4K	﹤0.01%	1937
2022 Q3	$968K	Buy	36,666 +842	+2%	+$26K	﹤0.01%	1830
2022 Q2	$1.03M	Sell	35,824 -20,171	-36%	-$602K	﹤0.01%	1809
2022 Q1	$1.93M	Buy	55,995 +14,902	+36%	+$527K	﹤0.01%	1515
2021 Q4	$1.8M	Buy	41,093 +30,006	+271%	+$1.42M	﹤0.01%	1611
2021 Q3	$562K	Buy	11,087 +818	+8%	+$42.6K	﹤0.01%	2294
2021 Q2	$534K	Buy	10,269 +510	+5%	+$23.9K	﹤0.01%	2329
2021 Q1	$446K	Buy	+9,759	New	+$477K	﹤0.01%	2365

Other funds holding IDNA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CCA

Clearwater Capital Advisors Hoffman Estates, Illinois $1.36B AUM 18.79% 1-Year Est. Return

CCA

Cora Capital Advisors Marlton, New Jersey $356M AUM 27.17% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Raymond James Financial Services Advisors's IDNA Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 0.89% in Q3 2024, selling an estimated $5.04K and leaving 23,028 shares worth $567K. The position accounts for ﹤0.01% of the portfolio, ranked #2530.

Raymond James Financial Services Advisors first reported a position in IDNA in Q1 2021 and has held it in 15 quarters since. The position peaked at $1.93M in Q1 2022. 53 funds tracked by Wall St. Rank hold IDNA as of Q3 2024.

Raymond James Financial Services Advisors held 23,028 shares of iShares Genomics Immunology and Healthcare ETF worth $567K as of Q3 2024.
Raymond James Financial Services Advisors sold 207 iShares Genomics Immunology and Healthcare ETF shares in Q3 2024, an estimated $5.04K.
iShares Genomics Immunology and Healthcare ETF made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2530 holding.
Raymond James Financial Services Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2021 and has held it in 15 quarters since.
Raymond James Financial Services Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $1.93M in Q1 2022.
53 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.